Breaking AI & Tech News Analyzed

The world’s largest randomised trial of a multi‑cancer early detection (MCED) blood test, involving 142,942 NHS participants, did not achieve its main aim of cutting late‑stage cancer diagnoses, according to data presented at the ASCO annual meeting in Chicago.Trial Overview and Primary ObjectiveThe study enrolled adults aged 50‑77 with no cancer symptoms, assigning half to annual Galleri testing alongside standard screening and the other half to standard screening alone. Positive Galleri results triggered diagnostic follow‑up, mirroring the protocol for symptomatic participants in both arms.Key Findings and Statistical OutcomesParticipants: 142,942 screened over three years.Primary endpoint: Combined stage III and IV diagnoses across 12 pre‑specified cancers.Result: No statistically significant reduction in advanced‑stage cancers in the Galleri arm versus control.Secondary signal: Stage IV cancers fell by 14% in the Galleri group, a finding the company Grail highlighted as encouraging.Dr Julie Gralow, ASCO’s chief medical officer, noted the trial showed “some encouraging trends toward tumour downstaging” but emphasized the primary endpoint was not met.Implications for NHS Cancer Screening StrategyExperts such as Prof Richard Houlston (Institute of Cancer Research) warned that the lack of a primary‑endpoint hit undermines any justification for nationwide adoption of Galleri. Prof Peter Johnson, NHS England’s national clinical director for cancer, said the NHS will scrutinise the full data before deciding on future implementation.The trial’s outcome raises questions about the cost‑effectiveness of MCED tests at population scale and may temper enthusiasm for rapid integration into existing screening programmes.Future Directions and Remaining QuestionsMortality outcomes, expected in the next few years, will be critical to assess whether earlier detection translates into survival benefits. Researchers and policymakers will likely await these results before committing to broader rollout, while Grail may refine its assay based on the secondary findings.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.